How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Employment Drug Testing Service Market
- By Testing Method: Urine Drug Testing, Hair Follicle Drug Testing, Saliva Drug Testing, Blood Drug Testing, Sweat Patch Testing
- By Service Provider Type: Laboratory-Based Testing Services, On-Site Testing Services, Mobile Testing Services, Third-Party Administrator (TPA) Services
- By End-User Industry: Healthcare and Pharmaceuticals, Transportation and Logistics, Construction and Manufacturing, Government and Public Sector, Retail and Hospitality
- By Panel Type: 5-Panel Drug Test, 10-Panel Drug Test, 12-Panel Drug Test, Expanded Panel Testing
- By Testing Purpose: Pre-Employment Screening, Random Employee Testing, Post-Accident Testing, Return-to-Duty Testing, Reasonable Suspicion Testing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urine Drug Testing leads By Testing Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Employment Drug Testing Service Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Testing Method 5
Service Provider Type 4
End-User Industry 5
Panel Type 4
Testing Purpose 5
Companies profiled
Labcorp Drug Development (Covance)
Quest Diagnostics
Alere Inc. (Abbott)
MRO Corporation
CRL (Clinical Reference Laboratory)
MedTox Laboratories
Omega Laboratories
US Drug Test Centers
Concentra Inc.
DrugScan Inc.
ACM Global Laboratories
MediCorp Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Labcorp Drug Development (Covance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Quest Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Alere Inc. (Abbott)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →MRO Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →CRL (Clinical Reference Laboratory)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MedTox Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Omega Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →US Drug Test Centers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Concentra Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →DrugScan Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →ACM Global Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →MediCorp Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Molecular Testing Labs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →MRO Labs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →NMS Labs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,833M by 2033 · 11.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urine Drug Testing33.1
- Hair Follicle Drug Testing19.9
- Saliva Drug Testing18.1
- Blood Drug Testing14.8
- Sweat Patch Testing14.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$251.0M → $602.3M · 11.6%
Europe$174.9M → $404.8M · 11.1%
Asia Pacific$159.7M → $429.8M · 13.2%
Latin America$98.9M → $263.3M · 13.0%
Middle East and Africa$76.1M → $192.9M · 12.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.582026
11.582027
11.592028
11.602029
11.612030
11.642031
11.652032
11.662033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Labcorp Drug Development (Covance)11.4
- Quest Diagnostics12.2
- Alere Inc. (Abbott)13.4
- MRO Corporation12.5
- CRL (Clinical Reference Laboratory)10.4
- MedTox Laboratories12.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Testing Method24.5%
Service Provider Type16.2%
End-User Industry17.7%
Panel Type14.2%
Testing Purpose27.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.8
- Europe21.4
- Asia Pacific22.7
- Latin America13.9
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Labcorp Drug Development (Covance) | 82 | 78 | 75 | 97 | 74 | 74 | 80 |
| Quest Diagnostics | 75 | 72 | 87 | 85 | 85 | 88 | 82 |
| Alere Inc. (Abbott) | 87 | 63 | 86 | 79 | 72 | 73 | 77 |
| MRO Corporation | 70 | 75 | 77 | 65 | 66 | 67 | 70 |
| CRL (Clinical Reference Laboratory) | 63 | 63 | 59 | 60 | 52 | 54 | 59 |
| MedTox Laboratories | 54 | 56 | 53 | 68 | 65 | 62 | 60 |
| Omega Laboratories | 41 | 63 | 40 | 40 | 57 | 53 | 49 |
| US Drug Test Centers | 53 | 55 | 47 | 54 | 50 | 51 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Labcorp Drug Development (Covance)
- Quest Diagnostics
- Alere Inc. (Abbott)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Labcorp Drug Development (Covance) | ◐ | ◐ | ◐ | ◐ | ✓ | − |
| Quest Diagnostics | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Alere Inc. (Abbott) | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| MRO Corporation | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| CRL (Clinical Reference Laboratory) | − | ◐ | ◐ | ◐ | − | ◐ |
| MedTox Laboratories | − | − | − | ◐ | − | − |
| Omega Laboratories | ◐ | ◐ | − | ◐ | − | − |
| US Drug Test Centers | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Quest Diagnostics82
2Labcorp Drug Development (Covance)80
3Alere Inc. (Abbott)77
4MRO Corporation70
5MedTox Laboratories60
6CRL (Clinical Reference Laboratory)59
7US Drug Test Centers52
8Omega Laboratories49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Labcorp Drug Development (Covance)Quest Diagnostics
Challenger2
Strong scale, closing on the leaders.
Alere Inc. (Abbott)MRO Corporation
Contender2
Focused players with pockets of strength.
CRL (Clinical Reference Laboratory)MedTox Laboratories
Niche2
Specialists in a single segment or region.
Omega LaboratoriesUS Drug Test Centers
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Testing Method in North America, then scale across Employment Drug Testing Service Market — a $72M beachhead inside a $1.27B market.
Beachhead (SOM)$72Mobtainable near-term
Serviceable (SAM)$432Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Urine Drug Testing
Best fit — highest urgency & budget in Testing Method.
Economic buyer75 fit
Hair Follicle Drug Testing
Strong fit — clear ROI and a fast path to value.
End user67 fit
Saliva Drug Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Testing Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Provider Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User Industry
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Testing Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Employment Drug Testing Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation11%
Closed-won7%
$18.0KCAC
$106KLTV
5.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Employment Drug Testing Service Market is a durable-growth opportunity — $1.07B by 2033, compounding at 8.8%.
TAM · 2025$545Mtoday
TAM · 2033$1.07Bforecast
CAGR8.8%2027–2033
Cumulative$7.04Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.07BTotal addressable market
SAM$407MServiceable available market
SOM$84MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.8% CAGR
Demand compounds through 2033, outpacing GDP across Testing Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Testing Method moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.07BLarge & growingTAM by 2033 at 8.8% CAGR
$407MServiceable nowreachable with today’s model
$84MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$834MBear5.7% CAGR
$1.07BBase8.8% CAGR
$1.37BBull11.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Provider Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Employment Drug Testing Service Market — a $1.06B market by 2033. Plan: grow share from 7.2% to 11.3%.
Market size · 2033$1.06Btotal addressable
Market CAGR3.9%2027–2033
Target share11.3%from 7.2% today
Revenue ambition$120Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.2% | 11.3% | At risk |
| Revenue | $79M | $120M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 33.2% | 44.8% | At risk |
| Customer retention | 88.7% | 94.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Testing Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Service Provider Type capability
A defensible second engine — invest in Service Provider Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Testing Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Provider Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $15M capacity & capability investment
- Greenlight bolt-on M&A in Service Provider Type
- Authorise North America expansion plan
- Fund R&D program for Testing Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Employment Drug Testing Service Market conversation — a $9.43B market you can size, segment and defend in minutes.
Market size · 2033$9.43Btotal opportunity
Growth11.6%CAGR to 2033
Addressable buyers1,509+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Testing Method
Goal Grow share in Testing Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$70K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Labcorp Drug Development (Covance)Quest DiagnosticsAlere Inc. (Abbott)MRO CorporationCRL (Clinical Reference Laboratory)MedTox LaboratoriesOmega LaboratoriesUS Drug Test Centers+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Employment Drug Testing Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Employment Drug Testing Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Employment Drug Testing and Screening Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportGypsum-Free Lactic Acid Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportEmployee Wellness Platform Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportDesloratadine Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportThiophenol Market
Market size, share, segmentation and regional forecast.
$976M market · 2025 base year
View reportMilnacipran Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportEmployee Physical Examination Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportEmployee Biometric Screening Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportChymotrypsin Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportEmployee Assistance Program (EAP) Solutions Market
Employee Assistance Program (EAP) Solutions Market is valued at USD 4.4 Billion in 2025 and is …
$4.4B market · 2025 base year
View reportEmployee Assistance Program (EAP) Service Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportEmployee Assistance Program (EAP) Market
Employee Assistance Program (EAP) Market is valued at USD 3.75 Billion in 2025 and is expected …
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.